New anti-cancer drug breakthrough for prostate cancer – Griffith News

A new anti-cancer drug for prostate cancer overcomes the twin problems plaguing researchers for decades. It halts metastasis (tumour spread) and drug resistance.
Developed by Griffith University researcher Professor Des Richardson and colleagues from the University of Sydney, the drug known as DpC inhibits prostate specific antigen (PSA) as well as suppressing both androgen-dependent and independent arms of androgen receptor signalling.
The current gold standard for prostate cancer treatment i…

Click here to view the original article.